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1Chapter
Control and Prevention of 
Mastitis: Part Two
Oudessa Kerro Dego
Abstract
Current mastitis control measures are based upon good milking time hygiene; 
use of properly functioning milking machines; maintaining clean, dry, comfort-
able housing areas; segregation and culling of persistently infected animals; dry 
cow antibiotic therapy; proper identification and treatment of cows with clinical 
mastitis during lactation; establishing udder health goals; good record-keeping; 
regular monitoring of udder health status and periodic review of mastitis control 
program. Despite significant effect of these control measures when fully adopted, 
especially on contagious mastitis pathogens, these measures are not equally adopted 
by all farmers, and mastitis continues to be the most common and costly disease of 
dairy cattle throughout the world.
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1. Introduction
Despite significant effect of current ten points mastitis control measures when 
fully adopted, especially on contagious mastitis pathogens, these measures are not 
equally adopted by all farmers, and mastitis continues to be the most common and 
costly disease of dairy cattle throughout the world.
Despite decades of research to develop effective vaccines against major bacte-
rial mastitis pathogens such as Staphylococcus aureus, Streptococcus uberis, and E. 
coli, in dairy cows, effective intramammary immune mechanism is still poorly 
understood, perpetuating reliance on antibiotic therapies to control mastitis in 
dairy cows. Dependence on antibiotics is not sustainable because of its limited 
efficacy and increased risk of emergence of antimicrobial-resistant bacteria that 
pose serious public health threats. Most vaccination strategies for prevention of 
mastitis have focused on the enhancement of humoral immunity. Development 
of vaccines that induce a protective cellular immune response in the mammary 
gland has not been well investigated. The ability to induce cellular immunity, 
especially neutrophil activation and recruitment into the mammary gland, is one 
of the key strategies in the control of mastitis, but the magnitude and duration of 
increased cellular recruitment into the mammary gland will lead to a high number 
of somatic cells and poor milk quality. So the sustainable control measure is to 
develop effective vaccines that can induce potent and effective balanced (cellular 
and humoral) immunity, which prevents production loses and reduces clinical 
severity of mastitis without stimulating a marked inflammatory response of long 
duration.
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2. Hygienic control measures
Current mastitis control programs devised in the 1960s based on teat 
 disinfection, antibiotic therapy, and culling of chronically infected cows have 
led to considerable progress in controlling contagious mastitis pathogens such as 
Streptococcus agalactiae and Staphylococcus aureus. However, these procedures are 
much less effective against environmental pathogens, particularly Streptococcus 
uberis and E. coli which accounts for a significant proportion of subclinical 
and clinical mastitis in lactating and nonlactating cows and heifers [1–4]. The 
National Mastitis Council developed a 5-point mastitis control program in 1969 
to control the incidence rate of mastitis. This 5-point mastitis control program 
includes (1) dipping teats in an antiseptic solution before and after milking, 
(2) proper cleaning and maintenance of milking equipment, (3) early detection 
and treatment of infected animals, (4) dry cow therapy with long acting antibiot-
ics to reduce duration of existing infection and to prevent new intramammary 
infection, and (5) finally culling chronically infected animals [5, 6]. Later, it 
was updated to a 10-point plan, which includes more steps such as establishing 
udder health goals, maintain clean, dry, and comfortable environment, proper 
milking procedures, proper maintenance and use of milking equipment, good 
record keeping, management of clinical mastitis during lactation, effective 
dry cow management including blanket dry cow therapy, maintenance of good 
biosecurity for contagious pathogens and marketing chronically infected cows, 
regular monitoring of udder health status, and periodic review of mastitis control 
program [7]. Though these hygienic milking practices and control measures 
decrease bacterial spreading, transmission, and subsequent infection, it does not 
fully prevent infections from establishing. Dairy farmers utilize antimicrobials as 
a prophylactic treatment for the prevention of mastitis or as therapeutics to treat 
cases of mastitis [8].
3. Use of antimicrobials for treatment and prevention of mastitis
Antibiotics are used extensively in food-producing animals to combat disease 
and to improve animal productivity. On dairy farms, antibiotics are used for 
treatment and prevention of diseases affecting dairy cows, particularly mastitis, 
and are often administered routinely to entire herds to prevent mastitis during 
the dry or non-lactating period. Use of antibiotics in food-producing animals 
has resulted in healthier, more productive animals; lower disease incidence and 
prevalence rates, reduced morbidity and mortality; and production of abundant 
quantities of nutritious, high-quality, and low-cost food for human consump-
tion. In spite of these benefits, there is considerable concern from public health, 
food safety, and regulatory perspectives about use of antibiotics in food- 
producing animals [9]. There has been a growing concern with the extensive use 
of antimicrobials in production animals, especially non-therapeutic usage such 
as dry cow therapy in the case of dairy production, because of potential emer-
gence and spread of antimicrobial resistant bacteria. There has been an increased 
incidence of antimicrobial resistant bacteria both in human and animal medical 
services.
In almost all dairy farms in the US and many other countries, intramammary 
infusion of long-acting antimicrobials to dairy cows at dry-off is a routine practice 
to prevent bacterial IMI during the dry period. Over 90% of dairy farms in the US 
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infuse all udder quarters of all cows with antimicrobial (blanket dry cow therapy) 
regardless of their health status [8, 10, 11]. Antibiotics are also heavily used in dairy 
farms for the treatment of cases of mastitis and other diseases of dairy cows such 
as metritis, endometritis, retained placenta, lameness, and pneumonia. Similarly, 
antibiotics are also used for the treatment of neonatal calf diarrhea and pneumonia 
in dairy calves. This practice exposes a large number of animals to antimicrobials 
and increases the use of antimicrobials in dairy farms. Antimicrobials for the treat-
ment of mastitis are given through intramammary infusion as well as administered 
parenterally to dairy herd for the treatment of clinical (acute or peracute) mastitis 
and other periparturient diseases of dairy cows such as metritis, endometritis, 
retained placenta, and others like lameness and pneumonia. Antimicrobial treat-
ment for neonatal diarrhea and pneumonia are also given through parenteral 
routes. Some farms also feed waste milk (discarded milk during antibiotic treat-
ment, milk after parturition before allowed into the bulk tank) to heifer calves, 
which puts their gastrointestinal tract (GIT) microbiota under antibiotics pressure. 
Antibiotics infused into the mammary glands can be excreted to the environment 
through leakage of milk from the antibiotic-treated udder or absorbed into the 
body and enter the blood circulation and biotransformed (pharmacokinetics) 
in the liver or kidney and excreted from the body through urine or feces into the 
environments. Therefore, both parenteral and intramammary administration of 
antibiotics has a significant impact on other commensals or opportunistic bacteria 
in the gastrointestinal tract of dairy cows. This practice exposes large numbers of 
healthy cows to antimicrobials and also increases the use of antimicrobials in dairy 
farms, which in turn creates intense pressure on microbes in animals’ body and 
farm environments.
Intramammary infection may progress to clinical or subclinical mastitis [12]. 
Clinically infected udder is usually treated with antimicrobial, whereas subclini-
cally infected udder may not be diagnosed immediately and treated but remained 
infected and shedding bacteria through milk throughout lactation. The proportion 
of cure following treatment of mastitis varies and the variation in cure rate is multi-
factorial including cow factors (age or parity number, stage of lactation, and dura-
tion of infection, etc.), management factors (detection and diagnosis of infection 
and time from detection to treatment, availability of balanced nutrition, sanitation, 
etc.), factors related to antimicrobial use patterns (type, dose, route, frequency, and 
duration), and pathogen factors (type, species, number, pathogenicity or virulence, 
resistance to antimicrobial, etc.) [13, 14].
The most common antibiotics used to treat mastitis include cephalosporins 
(53.2%), followed by lincosamide (19.4%) and non-cephalosporin β-lactam antibi-
otics (19.1%) [8]. The problem with the use of non-selective blanket antimicrobials 
administration to dairy cows as a prophylactic control of mastitis is that they put 
selective pressure on both mastitis-causing bacteria as well as commensal bacteria 
in the animals’ body [15, 16]. The ultimate result may not be different but the 
exposure level to antibiotics and its biotransformed products are different for the 
bacteria in the gut, in the mammary glands, and dairy farm environments during 
use of antimicrobials for prevention and treatment of mastitis and other diseases 
of dairy cattle. This selective pressure can result in antimicrobial resistant bacteria 
that become difficult to clear and persistent on farms and spread among animals 
[17]. The antimicrobial resistant bacteria or their genes may spread from these 
sources to human or animals or to other bacteria. McAllister et al. [18] found that 
CNS could potentially transfer penicillin, cephalosporins, and fluoroquinolones 
resistant genes to S. aureus. The transfer of these antibiotic resistance genes could 
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lead to the development of antimicrobial resistant bacteria including methicillin-
resistant S. aureus (MRSA) [18]. Treatment of Staphylococcus aureus mastitis with 
antibiotics is of limited success which may dictate the culling of the animal [14, 19]. 
Until recently, MRSA was a common antimicrobial resistant strain mainly found in 
human hospitals; however, recent findings indicated that it has also been increas-
ingly isolated from cattle herds [20]. The major problem with MRSA is that it is 
mostly resistant to multiple commonly used antimicrobials (multidrug resistant) 
and difficult to control and eliminate [21]. On an average, the cure rate of lactating 
cow therapy against S. aureus mastitis is about 30% or less [22]. Currently, there is 
no effective vaccine against bovine S. aureus mastitis [23], and since treatment is of 
limited efficacy, control of S. aureus mastitis focuses on prevention of contamina-
tion and spread, rather than treatment [14, 19].
Antimicrobial resistance is a growing problem in Staphylococcus aureus mastitis. 
Antimicrobial resistance helps bacteria to stay alive after treatment with antibiot-
ics and some of the mechanisms of resistance are the presence of antimicrobial 
resistance genes that can spread by horizontal transfer from bacteria to bacteria by 
mobile genetic elements such as plasmids, phages, and pathogenicity islands [24]. 
This resistance can also occur through random mutations when the bacteria are 
under stress [25]. In the cases of mastitis, the prevalence of antimicrobial resistant 
bacteria seems to be increasing at least for some antimicrobials. Studies reported 
over 50% of isolates that cause mastitis were resistant to either beta lactam drugs or 
penicillin [26]. In human medicine, methicillin resistant S. aureus (MRSA) is a huge 
problem because MRSA strains are resistant to most of antibiotics making them 
very difficult or impossible to treat. There have also been reports of cases of bovine 
mastitis caused by MRSA [27–30]. Some report that these infections are due to the 
human strain, but others have found MRSA strains of bovine origin [21, 31]. These 
authors suggested that MRSA strains isolated from bovine probably gain resistance 
from human MRSA strain through transfer of resistance genes [32].
Waller et al. [33] evaluated the antimicrobial susceptibility of CNS and found 
a difference across the species on β-lactamase production. Similarly, Sawant et al. 
[34] found that 18% and 46 of the S. chromogenes and S. epidermidis isolates produce 
β-lactamase, respectively. Sampimon et al. [35] also found a 70% resistance to 
penicillin in S. epidermidis, but more importantly found that 30% of the CNS were 
resistant to more than one antimicrobial.
From antimicrobial resistance perspective, environmental mastitis pathogens 
are very important for two reasons: (1) some members of environmental mastitis 
pathogens are either normal microflora or opportunistic pathogens in the gastro-
intestinal tract of dairy cows and frequently exposed to antimicrobials directly 
through oral or indirectly through parenteral routes; (2) despite strain variation, 
some of them are highly pathogenic for human (for example, E. coli 0157:H7 is 
normal microflora in the rectum of cattle). Of significant concern is the potential 
for human infection by antimicrobial-resistant environmental mastitis pathogens 
such as extended-spectrum beta-lactam resistant E. coli directly through contact 
with carrier animal or indirectly through the food chain. Some of the Gram-
negative environmental mastitis pathogens, such as E. coli, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. are the 
greatest threat to human health due to the emergence of strains that are resistant to 
all or most available antimicrobials [36, 37].
In general, the antimicrobial resistance of mastitis pathogens varies with dairy 
farms and bacterial species within and among dairy farms [11, 38–42]. However, 
the antimicrobial-resistance status of human pathogenic environmental mastitis 
pathogens, especially the resistance status of Gram-negative environmental mastitis 
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pathogens in the family of Enterobacteriaceae, is yet to be determined. Monitoring 
antimicrobial resistance patterns of bacterial isolates from cases of mastitis is 
important for treatment decisions and proper design of mitigation measures. It 
also helps to determine emergence, persistence, and potential risk of the spread 
of antimicrobial-resistant bacteria and resistome to human, animal, and environ-
ment [17, 43]. The prudent use of antimicrobials in dairy farms reduces emergence, 
persistence, and spread of antimicrobial-resistant bacteria and resistome from dairy 
farms to human, animal, and environment.
4. Vaccines
Several vaccine studies were conducted over the years as controlled experi-
mental and field trials. Some of the most common mastitis pathogens that have 
been targeted for vaccine development are S. aureus, S. agalactiae, S. uberis, and E. 
coli [44]. Most of these experimental and some commercial vaccines are bacterins 
which are inactivated whole organism, and some vaccines contained subunits of the 
organism such as surface proteins [45], toxins, or polysaccharides.
All coliform mastitis vaccine formulations use Gram-negative core antigens 
to produce non-specific immunity directed against endotoxin (LPS) [44]. The 
principle of these bacterins is based upon their ability to stimulate production of 
antibodies directed against common core antigens that Gram-negative bacteria 
share. These vaccines do not prevent new intramammary infection but significantly 
reduced the clinical severity of the infection [46–48]. Experimental challenge stud-
ies have demonstrated that J5 vaccines are able to reduce bacterial counts in milk 
and resulted in fewer and less severe clinical symptoms [47]. Vaccinated cows may 
become infected with Gram-negative mastitis pathogens at the same rate as control 
animals but have a lower rate of development of clinical mastitis [48], reduced 
duration of infection [46], less loss of milk production, culling, and death losses 
[49, 50]. The Eviracor®J5 E. coli vaccine (Zoetis, Kalamazoo, MI), [51, 52], as well 
as the UBAC® S. uberis vaccine (Hipra, Amir, Spain), [53] are similar to vaccination 
with nonspecific killed whole bacterial cells (bacterin vaccines), achieving only 
partial reduction in clinical severity of mastitis.
Despite several mastitis vaccine trials conducted against S. aureus mastitis 
[54–65], all field trials have either been unsuccessful or had limited success. There 
are two commercial vaccines for Staphylococcus aureus mastitis on the market, 
Lysigin® (Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO) in the United 
States and Startvac® (Hipra S.A, Girona, Spain) in Europe and Canada [66]. None 
of these vaccines confer protection in field trials as well as under controlled experi-
mental studies [54, 58, 62, 67]. Several field trials and controlled experimental stud-
ies have been conducted testing the efficacy of Lysigin® and Startvac® and results 
from those studies have shown some interesting results, namely a reduced incidence, 
severity, and duration of mastitis in vaccinated cows compared to non-vaccinated 
control cows [54, 62, 68]. Contrary to these observations, other studies failed to find 
an effect on improving udder health or showed no difference between vaccinated 
and non-vaccinated control cows [66, 69]. None of these bacterin-based vaccines 
prevents new S. aureus IMI [54, 58, 62, 67]. Differences found in these studies are 
mainly due to methodological differences (vaccination schedule, route of vaccina-
tion, challenge model, herd size, time of lactation, etc.) in testing the efficacy of 
these vaccines. It is critically important to have a good infection model that mimics 
natural infection and a model that has 100% efficacy in causing infection. Without a 
good challenge model, the results from vaccine efficacy will be inaccurate.
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5. Conclusions
Current mastitis control programs are based on teat disinfection, antibiotic ther-
apy, and culling of chronically infected cows. There is no single effective vaccine 
against any mastitis pathogen. The physiological nature of mammary glands where 
induced systemic immune responses need to cross from the body into the mammary 
glands, the dilution of effector immune responses by large volume of milk coupled 
with the ability of mastitis causing bacteria to develop immune evasion mechanisms 
and resistance to antimicrobials makes control of mastitis very difficult. However, 
developing improved and effective vaccines that overcomes these constraints using 
these quickly advancing molecular, genomic and immunological tools is a sustain-
able intervention approach.
Use of antibiotics in food-producing animals does contribute to increased 
antimicrobial resistance in dairy cattle and farm environments. Antimicrobial resis-
tance among dairy pathogens, particularly those bacterial strains that cause mastitis 
in dairy cattle, is not increasing at alarming rate. However, antimicrobial resistance 
among Gram-negative bacteria particularly those strains that mainly cause dis-
ease in humans are extremely high in dairy cattle and dairy farm environments. 
Transmission of an antimicrobial resistant mastitis pathogen and/or foodborne 
pathogen to humans could occur through direct contact with animal or indirectly 
through the food chain, if contaminated unpasteurized milk or dairy products made 
from contaminated raw milk is consumed, which is another very important reason 
why people should not consume raw milk. Likewise, resistant bacteria contaminat-
ing meat from culled dairy cows can easily transmit to humans through consump-
tion of undercooked meat.
We emphasize and recommend the prudent use of antibiotics in dairy farms. 
Strategies involving prudent use of antibiotics for treatment encompass identi-
fication of the pathogen causing the infection, determining the susceptibility/
resistance pattern of the pathogen to assess the most appropriate antibiotic to use 
for treatment, and a long enough treatment duration to ensure effective concentra-
tions of the antibiotic to eliminate the pathogen. Alternatives to use of antibiotics 
for maintaining animal health and productivity based on preventative measures, 
such as vaccination, improved nutrition, environmental sanitation, use of teat 
sealants, and selection for disease resistance genetic traits together with advances in 
more rapid pathogen detection and characterization systems will undoubtedly play 
an integral role in strategies aimed at improving dairy productivity with improved 
safety of dairy products for human consumption.
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